Clinical laboratory evaluations of aprepitant for the treatment of opioid depende

说明(申请人提供)：目前阿片类药物依赖的治疗将受益于增加一种非阿片类药物治疗药物。最近的临床前研究表明，NK1受体参与了阿片类药物的奖赏和戒断。这项研究建议研究一种临床上可用的NK1拮抗剂，阿片依赖患者的APRAPANT。根据阿片成瘾独特的行为和药理学特征，以及目前已知的治疗方法，我们认为任何潜在的阿片成瘾治疗药物的治疗机制都必须包括减少阿片类药物戒断的能力。这在治疗开始(例如戒毒)期间特别重要。此外，对于长期治疗和预防复发，重要的是管理药物渴望，改善压力的影响，并抑制阿片类药物的回报效应，如果患者确实经历了滑倒。因此，我们建议在临床实验室中使用急性阿片类药物奖励、强化和戒断以及应激和线索暴露反应的模型来研究重现。 公共卫生相关性：这项研究建议调查一种临床上可用的NK1拮抗剂，阿片类药物依赖患者的APPRAPANT。Areapant将在临床实验室进行测试，使用急性阿片类药物奖励、强化和戒断模型，以及压力和线索暴露反应模型。

DESCRIPTION (provided by applicant): Current treatments for opioid dependence would benefit by the addition of a non-opioid based treatment medication. Recent pre-clinical studies have demonstrated the involvement of the NK1 rector in opioid reward and withdrawal. This study proposes to investigate a clinically available NK1 antagonist, aprepitant, in opioid dependent patients. Based on the unique behavioral and pharmacological characteristics of opioid addiction, and what is known of the currently employed treatments, we propose that the therapeutic mechanism of any potential opioid addiction treatment medication must include the ability to reduce opioid withdrawal. This is of particular importance during treatment initiation (e.g., detoxification). In addition, for long-term treatment and relapse prevention it is important to manage drug craving, to ameliorate the effects of stress, and inhibit the rewarding effects of opioids if patients do experience a slip. Therefore, we propose to study aprepitant in the clinical laboratory, using models of acute opioid reward, reinforcement and withdrawal, as well as stress- and cue-exposure responding. PUBLIC HEALTH RELEVANCE: This study proposes to investigate a clinically available NK1 antagonist, aprepitant, in opioid dependent patients. Aprepitant will be tested in the clinical laboratory, using models of acute opioid reward, reinforcement and withdrawal, as well as stress- and cue-exposure responding.